ArticleScientific reports2015
Exometabolom analysis of breast cancer cell lines: Metabolic signature.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- On the Quest for Biomarkers: A Comprehensive Analysis of Modified Nucleosides in Ovarian Cancer Cell Lines.Cells · 2025Article
- [Current advances in the analysis of free RNA modified nucleosides by high performance liquid chromatography-tandem mass spectrometry].Se pu = Chinese journal of chromatography · 2025Review
- Serum Metabolic Fingerprints Characterize Systemic Lupus Erythematosus.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Article
- A functional gene module identification algorithm in gene expression data based on genetic algorithm and gene ontology.BMC genomics · 2023Article
- Analysis of the microbial diversity in takin (Frontiers in microbiology · 2023Article
- How previous treatment changes the metabolomic profile in patients with metastatic breast cancer.Archives of gynecology and obstetrics · 2022Article
- Ultrasensitive Simultaneous Detection of Multiple Rare Modified Nucleosides as Promising Biomarkers in Low-Put Breast Cancer DNA Samples for Clinical Multi-Dimensional Diagnosis.Molecules (Basel, Switzerland) · 2022Article
- Article
- Pseudouridine as a novel biomarker in prostate cancer.Urologic oncology · 2021Review
- Application of metabolomics in the diagnosis of breast cancer: a systematic review.Journal of Cancer · 2020Review
- Human acireductone dioxygenase (HsARD), cancer and human health: Black hat, white hat or gray?Inorganics · 2019Article
- Structural and biochemical characterization of Rv0187, an O-methyltransferase from Mycobacterium tuberculosis.Scientific reports · 2019Article
- Metabolic Phenotyping of Anks3 Depletion in mIMCD-3 cells - a Putative Nephronophthisis Candidate.Scientific reports · 2018Article
- Protein biomarkers for subtyping breast cancer and implications for future research.Expert review of proteomics · 2018Review
- Activation of polymeric nanoparticle intracellular targeting overcomes chemodrug resistance in human primary patient breast cancer cells.International journal of nanomedicine · 2018Article
- The three-legged stool of understanding metabolism: integrating metabolomics with biochemical genetics and computational modeling.AIMS microbiology · 2018Article
- Current Challenges toward In Vitro Cellular Validation of Inorganic Nanoparticles.Bioconjugate chemistry · 2017Review
- The Impact of Soy Isoflavones on MCF-7 and MDA-MB-231 Breast Cancer Cells Using a Global Metabolomic Approach.International journal of molecular sciences · 2016Article
- Interaction between APC and Fen1 during breast carcinogenesis.DNA repair · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer cells show characteristic effects on cellular turnover and DNA/RNA modifications leading to elevated levels of excreted modified nucleosides. We investigated the molecular signature of different subtypes of breast cancer cell lines and the breast epithelial cell line MCF-10A. Prepurification of cell culture supernatants was performed by cis-diol specific affinity chromatography using boronate-derivatized polyacrylamide gel. Samples were analyzed by application of reversed phase chromatography coupled to a triple quadrupole mass spectrometer. Collectively, we determined 23 compounds from RNA metabolism, two from purine metabolism, five from polyamine/methionine cycle, one from histidine metabolism and two from nicotinate and nicotinamide metabolism. We observed major differences of metabolite excretion pattern between the breast cancer cell lines and MCF-10A, just as well as between the different breast cancer cell lines themselves. Differences in metabolite excretion resulting from cancerous metabolism can be integrated into altered processes on the cellular level. Modified nucleosides have great potential as biomarkers in due consideration of the heterogeneity of breast cancer that is reflected by the different molecular subtypes of breast cancer. Our data suggests that the metabolic signature of breast cancer cell lines might be a more subtype-specific tool to predict breast cancer, rather than a universal approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.